NASDAQ:CABA Cabaletta Bio Q3 2026 Earnings Results & Report $1.42 -0.09 (-5.67%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Cabaletta Bio beat analyst earnings expectations in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$0.28 versus the -$0.3174 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeBefore Market OpensConference Call7:00 AM ET Cabaletta Bio EPS ResultsActual EPS-$0.28Consensus EPS -$0.3174Beat/MissBeat by +$0.0374One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCabaletta Bio Revenue ResultsActual RevenueN/AExpected Revenue$1.67 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cabaletta Bio Q3 2026 Earnings FAQ Did Cabaletta Bio beat earnings estimates for Q3 2026? Cabaletta Bio (NASDAQ:CABA) reported earnings of -$0.28 per share for Q3 2026, beating the consensus estimate of -$0.3174. The report was announced on Thursday, November 5, 2026. Cabaletta Bio Earnings HeadlinesCabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data At ACR Convergence 2026November 10 at 8:52 AM | marketscreener.comMCabaletta Bio Reports Positive Phase 1/2 Data For Rese-cel In Autoimmune Diseases; Stock UpNovember 9 at 7:48 AM | rttnews.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 10 at 1:00 AM | Porter & Company (Ad)FY2030 EPS Estimate for Cabaletta Bio Decreased by AnalystNovember 9 at 1:59 AM | americanbankingnews.comCabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across ...November 8 at 2:47 PM | markets.businessinsider.comCabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune DiseasesNovember 8 at 10:00 AM | globenewswire.comSee More Cabaletta Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cabaletta Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cabaletta Bio and other key companies, straight to your email. Email Address About Cabaletta BioCabaletta Bio (NASDAQ:CABA) is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression. Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells. Cabaletta is evaluating CABA-201 in several autoimmune conditions, including systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies and generalized myasthenia gravis. The company has also developed targeted chimeric autoantibody receptor T-cell, or CAAR T, programs intended to address specific autoimmune diseases. Founded in 2017 and headquartered in Philadelphia, Pennsylvania, Cabaletta Bio serves the biotechnology and biopharmaceutical markets through its research and clinical development activities. Its therapies remain investigational and have not been established as safe or effective for commercial use by regulatory authorities.View Cabaletta Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
